LabCorp has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, LabCorp, MAY 4, 2015, View Source [SID1234503571]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Vertex Pharmaceuticals has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Vertex Pharmaceuticals, MAY 4, 2015, View Source [SID1234503573]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pharmacyclics has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Pharmacyclics, MAY 4, 2015, View Source [SID1234503575]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 4, 2015 Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) reported the signing of an extension to the existing collaboration agreement with AstraZeneca to commence scale up of a dendrimer enhanced oncology molecule ("DEP conjugate") for further development (Press release, Starpharma, MAY 4, 2015, View Source [SID:1234506574]).

During 2014 Starpharma and AstraZeneca conducted a series of studies in which Starpharma’s DEP drug delivery technology was used to modify a development candidate from AstraZeneca’s cancer pipeline. This program has been successful with key enhancements for the DEP conjugate now having been demonstrated by AstraZeneca in animal models. Based on these results AstraZeneca is now conducting further pre-clinical studies with a view to subsequent commencement of clinical trials, if results of the current work continue to be positive.

"We are delighted that the DEP conjugate has performed so well in extensive testing by AstraZeneca over the last year or so" said Dr Jackie Fairley, Chief Executive Officer of Starpharma. "The collaboration has been a very productive one and AstraZeneca has been a tremendous partner. We look forward to working closely with them through the next stage of the program as the DEP conjugate is advanced for further development and clinical studies."

Andrew Potts, Project Director from AstraZeneca’s Pharmaceutical Development organisation commented: "Combining the great science that’s happening in our labs with the most innovative biotech science is an essential part of our plans to deliver the next generation of medicines. This collaboration will enable us to further harness the DEP technology supporting our plans to accelerate evaluation of a novel molecule within our oncology portfolio.’

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 1, 2015 Eleison Pharmaceuticals LLC, a specialty pharmaceutical company developing life-saving therapeutics for rare cancers reported that it has successfully completed the first stage of its Phase II study of ILC (Inhaled Lipid-complexed Cisplatin), for the treatment of patients with pediatric osteosarcoma (bone cancer), with all 19 patients enrolled in this stage of the study having reached the study endpoint (Press release, Eleison Pharmaceuticals, MAY 1, 2015, View Source [SID1234517397]). The study has been enrolling patients at 15 of the leading U.S. hospitals and medical centers. More information about the study may be found at the www.clinicaltrials.gov website.
"In this study, we were evaluating if ILC may delay or prevent further pulmonary relapses in osteosarcoma patients", commented Mr. Edwin Thomas, CEO of Eleison. "We are very encouraged by the data generated by the study as 13 of the 19 patients experienced a relapse-free interval longer than the predicted relapse-free interval", further commented Mr. Thomas. Eleison is continuing to evaluate the study data and is planning to commence a pivotal registrational clinical trial of ILC later this year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!